Key result
Increased fat-mass, low apelin, and high visfatin levels correlated with carotid plaque vulnerability, while atorvastatin-induced apelin and LDL-C changes improved plaque stability.
Why the study?
Does atorvastatin therapy and modification of adipokines (apelin and visfatin) improve carotid plaque vulnerability (GSM score) in overweight patients with carotid stenosis?
Cohort (n=112)
Does atorvastatin therapy and modification of adipokines (apelin and visfatin) improve carotid plaque vulnerability (GSM score) in overweight patients with carotid stenosis?
In overweight patients with carotid stenosis, atorvastatin therapy improves carotid plaque stability, which is independently associated with increases in apelin and reductions in LDL-C.
Answers are grounded in this paper and cite their sources.
Atorvastatin-linked apelin rises may stabilize carotid plaques in overweight patients; leaves open whether adipokine modulation causally improves outcomes.
BACKGROUND: In patients with carotid stenosis, we prospectively investigated the association of novel adipokines, apelin and visfatin, with gray-scale median (GSM) score, a valid index of carotid plaque vulnerability. We also assessed the impact of atorvastatin therapy on the above biochemical and imaging markers. MATERIALS AND METHODS: Seventy-four overweight [body-mass index (BMI) > 25 kg/m(2) , fat-mass > 30%], statin-free patients, with carotid stenosis, but without indications for intervention were enrolled. Thirty-eight age-, sex- and BMI-matched healthy subjects served as healthy controls (HC). All patients received gradual titrated (10-80 mg) atorvastatin therapy to target LDL-C < 100 mg/dL. GSM score, blood pressure (BP), fat-mass, lipid profile, and serum high-sensitivity C-reactive protein (hsCRP), apelin and visfatin levels were obtained at baseline and after 24 months. RESULTS: At baseline, patients with carotid atherosclerosis had worse lipid profile, lower apelin and higher systolic BP, hsCRP, visfatin levels compared with HC (P < 0·05). Notably, decreased apelin (P < 0·001) and GSM score (P = 0·010), while increased visfatin (P = 0·019) and hsCRP (P = 0·039) levels were found in symptomatic rather than asymptomatic patients. At baseline, GSM score correlated with fat-mass, BMI, LDL-C, visfatin and apelin (P < 0·05). Apelin, visfatin and fat-mass remained independent determinants of baseline GSM score (R(2) = 0·391, P = 0·007). In parallel, we found that apelin increment and LDL-C reduction were independently associated with the atorvastatin-induced GSM increase (R(2) = 0·411, P = 0·011). CONCLUSION: Increased fat-mass, low apelin and high visfatin serum levels seem to correlate with carotid plaque vulnerability in patients with carotid stenosis. The atorvastatin-induced modification of apelin and LDL-C may beneficially affect carotid plaque stability.
No takes yet. Share an insight, caveat, or question.
Kadoglou et al. (2012) conducted a cohort in carotid stenosis (n=112). Adipokines (apelin and visfatin) and atorvastatin vs. Healthy controls was evaluated on gray-scale median (GSM) score (p=0.007). Increased fat-mass, low apelin, and high visfatin levels correlated with carotid plaque vulnerability, while atorvastatin-induced apelin and LDL-C changes improved plaque stability.
Synapse has enriched 10 related papers. Consider them for comparative context: